

In the specification, please make the following amendments as set forth below.

Between lines 13 and 14 at page 10 of the specification, please insert the following section title and paragraph containing a brief description of the drawings.

Brief Description of the Drawings

Figure 1 illustrates a synthetic scheme for producing compounds of this invention.

Figure 2 is a plot of the absorption and emission spectra of the compounds 2a and 4a of this invention.

Figure 3 is an illustration of the x-ray crystal structure of compound 2b of this invention.

Figure 4 is a fluorescent microscopic image of cellular localization of the compound 2a in HeLa cells.

Figure 5 is an image of stained HeLa cells exhibiting cellular localization of the compound 2a.

Figures 6a and 6b are plots of cellular uptake of the compound 2a in HeLa cells (Figure 6a) and MRC5 cells (Figure 6b).

Figure 7 is a plot of the efflux of the compound 2a in HeLa cells.

Figure 8 is a plot of a dose response of the compound 2a in HeLa cells.

Figure 9 is a plot of the toxicity of haematoporphyrin in HeLa cells.

Figure 10 is a plot of the toxicity of haematoporphyrin in MRC5 cells.

Figure 11 is a plot of the toxicity of the compound 2a in HeLa cells.

Figure 12 is a plot of the toxicity of the compound 2a in MRC5 cells.

Figure 13 is a plot of the toxicity of the compound 2b in HeLa cells.

Figure 14 is a plot of the toxicity of the compound 2b in MRC5 cells.

Figure 15 is a fluorescent microscopic image of F-actin stained HeLa cells treated with compound 2a and no light exposure.

Figure 16 is a fluorescent microscopic image of F-actin stained HeLa cells treated with compound 2a and a 30 minute light exposure.

Figures 17 through 19 are confocal microscopic images of the cytoplasmic localization of compound 2a.